ClinicalTrials.gg
CompletedNCT04321252Updated Dec 13, 2021Results posted

Study to Assess Safety, Tolerability and Phamacokinetics of KAE609 Administered Intravenously in Healthy Subjects

A Phase 1 interventional study of KAE609 and Placebo in Malaria, sponsored by Novartis Pharmaceuticals. Completed at 1 site in Belgium. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-12-13.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
57
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies in Malaria by Novartis — 3 open to participants now, 3 under way, none of them phase 3. Malaria · Novartis.

Enrollment
11th of 21
57 · median 57
Started
2020
with 1 other
Phase 1
6 of 24
none open now
Registered
16th of 24
by date

Among the 24 studies in Malaria by Novartis, this one is the 11th largest by enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2020, is one of 6 in phase 1, and was the 16th registered.

Malaria

1,185 studies on the registry are indexed under Malaria; 80 are open to participants now.

Browse Malaria studies →

Open to participants now

3 of the 24 studies in Malaria by Novartis are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 52 Malaria studies recruiting now, 15 (29%) set no upper age limit and 34 (65%) stop at 75 or younger; 38 take children under 18; 32 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Malaria by Novartis, or all of them as a file.
02

Study summary

This was a randomized, subject and investigator-blinded, placebo-controlled, single and multiple ascending intravenous (iv) dose study in healthy subjects to assess the safety and tolerability of KAE609 given in the vein.

Read the detailed description

The study consisted of 2 parts: single-ascending dose (SAD) part and multiple ascending dose (MAD) part.

In Part A (Single-ascending dose (SAD) part), it was planned to recruit 6 active, 2 placebo subjects in each cohort:

  • Cohort A1: 10.5 mg/placebo
  • Cohort A2: 30 mg/placebo
  • Cohort A3: 75 mg/placebo
  • Cohort A4: 120 mg/placebo
  • Cohort A5: 210 mg/placebo

In Part B (Multiple-ascending dose (MAD) part), Subjects were assigned to one of the following treatment arms in a ratio of 2:1 (6 active, 3 placebo):

  • Cohort B1: 60 mg/placebo, every 24 hours (q24h) × 5 days
  • Cohort B2: 120 mg/placebo, every 24 hours (q24h) × 5 days

Eligible subjects were randomized to receive a single or q24h x 5 doses of either KAE609 or placebo. Safety, tolerability and pharmacokinetics were assessed over the period of 8 days for single dose and 12 days for multiple dose up to end of study visit for each subject.

03

Conditions studied

  • Malaria

Browse trials for

Keywords

  • safety
  • tolerability
  • pharmacokinetics
  • healthy volunteers
  • phase 1
  • malaria
  • intravenous
  • iv
  • KAE609
  • Placebo
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Healthy male and female subjects 18 to 55 years of age inclusive, and in good health as determined by past medical history, physical examination, vital signs, , and laboratory tests.
  • Subjects must weigh at least 50 kg to participate in the study, and must have a (BMI) within the range of 18.0 - 30.0 kg/m2.

Key Exclusion Criteria:

  • Use of other drugs within 5 half-lives of Screening, or within 30 days of dosing, whichever is longer; or longer if required by local regulations.
  • Significant illness which has not resolved within two (2) weeks prior to initial dosing.
  • Pregnant or nursing (lactating) women.
  • Women of , defined as all women physiologically capable of becoming pregnant.
  • Sexually active males unwilling to use a condom during intercourse while taking investigational drug and for at least 2 weeks after last dose of investigational drug.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
57 participants (actual)

Study arms

  • Experimental
    Cohort A1: 10.5 mg/placebo

    Single iv bolus dose of KAE609 or placebo administered at the clinical site by the study personnel.

    Drug: KAE609 · Drug: Placebo

  • Experimental
    Cohort A2: 30 mg/placebo

    Single iv bolus dose of KAE609 or placebo administered at the clinical site by the study personnel.

    Drug: KAE609 · Drug: Placebo

  • Experimental
    Cohort A3: 75 mg/placebo

    Single iv infusion dose of KAE609 or placebo administered at the clinical site by the study personnel.

    Drug: KAE609 · Drug: Placebo

  • Experimental
    Cohort A4: 120 mg/placebo

    Single iv infusion dose of KAE609 or placebo administered at the clinical site by the study personnel.

    Drug: KAE609 · Drug: Placebo

  • Experimental
    Cohort A5: 210 mg/placebo

    Single iv infusion dose of KAE609 or placebo administered at the clinical site by the study personnel.

    Drug: KAE609 · Drug: Placebo

  • Experimental
    Cohort B1: 60 mg/placebo, every 24 hours (q24h) × 5 days

    Multiple iv bolus doses of KAE609 or placebo administered at the clinical site by the study personnel.

    Drug: KAE609 · Drug: Placebo

  • Experimental
    Cohort B2: 120 mg/placebo, every 24 hours (q24h) × 5 days

    Multiple iv infusion doses of KAE609 or placebo administered at the clinical site by the study personnel.

    Drug: KAE609 · Drug: Placebo

Interventions

  • DrugKAE609

    * iv bolus administration over approximately 2 min for doses \< 75 mg (Cohorts A1, A2 and B1) * iv infusion over approximately 10 min for doses ≥ 75 mg (Cohorts A3, A4, A5 and B2)

  • DrugPlacebo

    matching placeo for iv administration

06

What researchers measure

Primary outcomes

  1. Number of Participants With On-Treatments Adverse Events, Serious Adverse Events, and Deaths

    The distribution of adverse events was done via the analysis of frequencies for Adverse Event (AEs), Serious Adverse Event (SAEs) and Deaths, through the monitoring of relevant clinical and laboratory safety parameters.

    Time frame: From study treatment start date till 30 days safety follow-up, assessed for up to 4 months

Secondary outcomes

  1. Part A - Pharmacokinetic of KAE609: Maximum Observed Plasma Concentration (Cmax)

    Venous whole blood samples were collected for activity-based pharmacokinetics characterization. Cmax was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics.

    Time frame: Day 1 (-1 hr, 2 min, 10 min, 30 min, 1 hr, 3 hr, 6 hr, 12 hr)

  2. Part A - Pharmacokinetic of KAE609: Time to Reach the Maximum Concentration After Drug Administration (Tmax)

    Venous whole blood samples were collected for activity-based pharmacokinetics characterization. Tmax was calculated from plasma concentration-time data using non-compartmental methods based on the actual time of sample collection and summarized using descriptive statistics.

    Time frame: Day 1 (-1 hr, 2 min, 10 min, 30 min, 1 hr, 3 hr, 6 hr, 12 hr)

  3. Part A - Pharmacokinetic of KAE609: Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUClast)

    Venous whole blood samples were collected for activity-based pharmacokinetics characterization. AUClast was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics.

    Time frame: Day 1 (-1 hr, 2 min, 10 min, 30 min, 1 hr, 3 hr, 6 hr, 12 hr)

  4. Part A - Pharmacokinetic of KAE609: Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUCinf)

    Venous whole blood samples were collected for activity-based pharmacokinetics characterization. AUCinf was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics.

    Time frame: Day 1 (-1 hr, 2 min, 10 min, 30 min, 1 hr, 3 hr, 6 hr, 12 hr)

  5. Part A - Pharmacokinetic of KAE609: Area Under the Plasma Concentration-time Curve From Time Zero to 24 Hours (AUC0-24hrs)

    Venous whole blood samples were collected for activity-based pharmacokinetics characterization. AUC0-24hrs was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics.

    Time frame: Day 1 (-1 hr, 2 min, 10 min, 30 min, 1 hr, 3 hr, 6 hr, 12 hr)

  6. Part A - Pharmacokinetic of KAE609: Terminal Elimination Half-life (T1/2)

    Venous whole blood samples were collected for activity-based pharmacokinetics characterization. T1/2 was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics.

    Time frame: Day 1 (-1 hr, 2 min, 10 min, 30 min, 1 hr, 3 hr, 6 hr, 12 hr)

  7. Part A - Pharmacokinetic of KAE609: Clearance From Plasma (CL) Following Drug Administration

    Venous whole blood samples were collected for activity-based pharmacokinetics characterization. CL was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics.

    Time frame: Day 1 (-1 hr, 2 min, 10 min, 30 min, 1 hr, 3 hr, 6 hr, 12 hr)

  8. Part A - Pharmacokinetic of KAE609: Apparent Volume of Distribution During Terminal Phase (Vz)

    Venous whole blood samples were collected for activity-based pharmacokinetics characterization. Vz was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics.

    Time frame: Day 1 (-1 hr, 2 min, 10 min, 30 min, 1 hr, 3 hr, 6 hr, 12 hr)

  9. Part B - Pharmacokinetic of KAE609: Maximum Observed Plasma Concentration (Cmax)

    Venous whole blood samples were collected for activity-based pharmacokinetics characterization. Cmax was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics.

    Time frame: Days 1 and 5 (-1 hr, 2 min, 10 min, 30 min, 1 hr, 3 hr, 6 hr, 12 hr)

  10. Part B - Pharmacokinetic of KAE609: Time to Reach the Maximum Concentration After Drug Administration (Tmax)

    Venous whole blood samples were collected for activity-based pharmacokinetics characterization. Tmax was calculated from plasma concentration-time data using non-compartmental methods based on the actual time of sample collection and summarized using descriptive statistics.

    Time frame: Days 1 and 5 (-1 hr, 2 min, 10 min, 30 min, 1 hr, 3 hr, 6 hr, 12 hr)

  11. Part B - Pharmacokinetic of KAE609: Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUClast)

    Venous whole blood samples were collected for activity-based pharmacokinetics characterization. AUClast was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics.

    Time frame: Day 5 (-1 hr, 2 min, 10 min, 30 min, 1 hr, 3 hr, 6 hr, 12 hr)

  12. Part B - Pharmacokinetic of KAE609: Area Under the Plasma Concentration-time Curve From Time Zero to 24 Hours (AUC0-24hrs)

    Venous whole blood samples were collected for activity-based pharmacokinetics characterization. AUC0-24hrs was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics.

    Time frame: Days 1 and 5 (-1 hr, 2 min, 10 min, 30 min, 1 hr, 3 hr, 6 hr, 12 hr)

  13. Part B - Pharmacokinetic of KAE609: Terminal Elimination Half-life (T1/2)

    Venous whole blood samples were collected for activity-based pharmacokinetics characterization. T1/2 was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics.

    Time frame: Days 1 and 5 (-1 hr, 2 min, 10 min, 30 min, 1 hr, 3 hr, 6 hr, 12 hr)

  14. Part B - Pharmacokinetic of KAE609: Clearance From Plasma (CL) Following Drug Administration

    Venous whole blood samples were collected for activity-based pharmacokinetics characterization. CL was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics.

    Time frame: Day 5 (-1 hr, 2 min, 10 min, 30 min, 1 hr, 3 hr, 6 hr, 12 hr)

  15. Part B - Pharmacokinetic of KAE609: Apparent Volume of Distribution During Terminal Phase (Vz)

    Venous whole blood samples were collected for activity-based pharmacokinetics characterization. Vz was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics.

    Time frame: Day 5 (-1 hr, 2 min, 10 min, 30 min, 1 hr, 3 hr, 6 hr, 12 hr)

07

Results

Posted Dec 13, 2021

Participant flow

This study was conducted in one center in Belgium.

Participant flow — Overall Study
MilestonePart A (Single-ascending Dose (SAD): Cohort A1 (KAE609 10.5 mg)Part A (Single-ascending Dose (SAD): Cohort A2 (KAE609 30 mg)Part A (Single-ascending Dose (SAD): Cohort A3 (KAE609 75 mg)Part A (Single-ascending Dose (SAD): Cohort A4 (KAE609 120 mg)Part A (Single-ascending Dose (SAD): Cohort A5 (KAE609 210 mg)Part A (Single-ascending Dose (SAD): Pooled PlaceboPart B (Multiple-ascending Dose (MAD): Cohort B1 (KAE609 60 mg)Part B (Multiple-ascending Dose (MAD): Cohort B2 (KAE609 120 mg)Part B (Multiple-ascending Dose (MAD): Pooled Placebo
Started666669666
Pk analysis set666660660
Completed666668666
Not completed000001000
Withdrew: Withdrawal by subject000001000

Outcome measures

PrimaryNumber of Participants With On-Treatments Adverse Events, Serious Adverse Events, and Deaths

The distribution of adverse events was done via the analysis of frequencies for Adverse Event (AEs), Serious Adverse Event (SAEs) and Deaths, through the monitoring of relevant clinical and laboratory safety parameters.

Time frame:
From study treatment start date till 30 days safety follow-up, assessed for up to 4 months
Reported as:
Count of participants · Participants
Number of Participants With On-Treatments Adverse Events, Serious Adverse Events, and Deaths
ParticipantsPart A (Single-ascending Dose (SAD): Cohort A1 (KAE609 10.5 mg)Part A (Single-ascending Dose (SAD): Cohort A2 (KAE609 30 mg)Part A (Single-ascending Dose (SAD): Cohort A3 (KAE609 75 mg)Part A (Single-ascending Dose (SAD): Cohort A4 (KAE609 120 mg)Part A (Single-ascending Dose (SAD): Cohort A5 (KAE609 210 mg)Part A (Single-ascending Dose (SAD): Pooled KAE609Part A (Single-ascending Dose (SAD): Pooled PlaceboPart B (Multiple-ascending Dose (MAD): Cohort B1 (KAE609 60 mg)Part B (Multiple-ascending Dose (MAD): Cohort B2 (KAE609 120 mg)Part B (Multiple-ascending Dose (MAD): Pooled KAE609Part B (Multiple-ascending Dose (MAD): Pooled Placebo
Adverse Events (AEs)0112610546104
Serious Adverse Events (SAEs)00010100000
Deaths00000000000
SecondaryPart A - Pharmacokinetic of KAE609: Maximum Observed Plasma Concentration (Cmax)

Venous whole blood samples were collected for activity-based pharmacokinetics characterization. Cmax was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics.

Time frame:
Day 1 (-1 hr, 2 min, 10 min, 30 min, 1 hr, 3 hr, 6 hr, 12 hr)
Reported as:
Mean · ng/mL
Part A - Pharmacokinetic of KAE609: Maximum Observed Plasma Concentration (Cmax)
ng/mLPart A (Single-ascending Dose (SAD): Cohort A1 (KAE609 10.5 mg)Part A (Single-ascending Dose (SAD): Cohort A2 (KAE609 30 mg)Part A (Single-ascending Dose (SAD): Cohort A3 (KAE609 75 mg)Part A (Single-ascending Dose (SAD): Cohort A4 (KAE609 120 mg)Part A (Single-ascending Dose (SAD): Cohort A5 (KAE609 210 mg)
Part A - Pharmacokinetic of KAE609: Maximum Observed Plasma Concentration (Cmax)412 ± 1011510 ± 10002910 ± 13405930 ± 11906590 ± 1290
SecondaryPart A - Pharmacokinetic of KAE609: Time to Reach the Maximum Concentration After Drug Administration (Tmax)

Venous whole blood samples were collected for activity-based pharmacokinetics characterization. Tmax was calculated from plasma concentration-time data using non-compartmental methods based on the actual time of sample collection and summarized using descriptive statistics.

Time frame:
Day 1 (-1 hr, 2 min, 10 min, 30 min, 1 hr, 3 hr, 6 hr, 12 hr)
Reported as:
Median · Hour (hr)
Part A - Pharmacokinetic of KAE609: Time to Reach the Maximum Concentration After Drug Administration (Tmax)
Hour (hr)Part A (Single-ascending Dose (SAD): Cohort A1 (KAE609 10.5 mg)Part A (Single-ascending Dose (SAD): Cohort A2 (KAE609 30 mg)Part A (Single-ascending Dose (SAD): Cohort A3 (KAE609 75 mg)Part A (Single-ascending Dose (SAD): Cohort A4 (KAE609 120 mg)Part A (Single-ascending Dose (SAD): Cohort A5 (KAE609 210 mg)
Part A - Pharmacokinetic of KAE609: Time to Reach the Maximum Concentration After Drug Administration (Tmax)0.167 (0.0167 to 0.167)0.0333 (0.0333 to 0.217)0.333 (0.183 to 0.550)0.167 (0.167 to 0.183)0.167 (0.167 to 0.200)
SecondaryPart A - Pharmacokinetic of KAE609: Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUClast)

Venous whole blood samples were collected for activity-based pharmacokinetics characterization. AUClast was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics.

Time frame:
Day 1 (-1 hr, 2 min, 10 min, 30 min, 1 hr, 3 hr, 6 hr, 12 hr)
Reported as:
Mean · h*ng/mL
Part A - Pharmacokinetic of KAE609: Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUClast)
h*ng/mLPart A (Single-ascending Dose (SAD): Cohort A1 (KAE609 10.5 mg)Part A (Single-ascending Dose (SAD): Cohort A2 (KAE609 30 mg)Part A (Single-ascending Dose (SAD): Cohort A3 (KAE609 75 mg)Part A (Single-ascending Dose (SAD): Cohort A4 (KAE609 120 mg)Part A (Single-ascending Dose (SAD): Cohort A5 (KAE609 210 mg)
Part A - Pharmacokinetic of KAE609: Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUClast)2690 ± 9779540 ± 164025400 ± 177053700 ± 2090060800 ± 11600
SecondaryPart A - Pharmacokinetic of KAE609: Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUCinf)

Venous whole blood samples were collected for activity-based pharmacokinetics characterization. AUCinf was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics.

Time frame:
Day 1 (-1 hr, 2 min, 10 min, 30 min, 1 hr, 3 hr, 6 hr, 12 hr)
Reported as:
Mean · h*ng/mL
Part A - Pharmacokinetic of KAE609: Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUCinf)
h*ng/mLPart A (Single-ascending Dose (SAD): Cohort A1 (KAE609 10.5 mg)Part A (Single-ascending Dose (SAD): Cohort A2 (KAE609 30 mg)Part A (Single-ascending Dose (SAD): Cohort A3 (KAE609 75 mg)Part A (Single-ascending Dose (SAD): Cohort A4 (KAE609 120 mg)Part A (Single-ascending Dose (SAD): Cohort A5 (KAE609 210 mg)
Part A - Pharmacokinetic of KAE609: Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUCinf)2770 ± 9909750 ± 173025600 ± 173057400 ± 2210062000 ± 11500
SecondaryPart A - Pharmacokinetic of KAE609: Area Under the Plasma Concentration-time Curve From Time Zero to 24 Hours (AUC0-24hrs)

Venous whole blood samples were collected for activity-based pharmacokinetics characterization. AUC0-24hrs was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics.

Time frame:
Day 1 (-1 hr, 2 min, 10 min, 30 min, 1 hr, 3 hr, 6 hr, 12 hr)
Reported as:
Mean · h*ng/mL
Part A - Pharmacokinetic of KAE609: Area Under the Plasma Concentration-time Curve From Time Zero to 24 Hours (AUC0-24hrs)
h*ng/mLPart A (Single-ascending Dose (SAD): Cohort A1 (KAE609 10.5 mg)Part A (Single-ascending Dose (SAD): Cohort A2 (KAE609 30 mg)Part A (Single-ascending Dose (SAD): Cohort A3 (KAE609 75 mg)Part A (Single-ascending Dose (SAD): Cohort A4 (KAE609 120 mg)Part A (Single-ascending Dose (SAD): Cohort A5 (KAE609 210 mg)
Part A - Pharmacokinetic of KAE609: Area Under the Plasma Concentration-time Curve From Time Zero to 24 Hours (AUC0-24hrs)1450 ± 3304540 ± 67313500 ± 223023200 ± 792026200 ± 3600
SecondaryPart A - Pharmacokinetic of KAE609: Terminal Elimination Half-life (T1/2)

Venous whole blood samples were collected for activity-based pharmacokinetics characterization. T1/2 was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics.

Time frame:
Day 1 (-1 hr, 2 min, 10 min, 30 min, 1 hr, 3 hr, 6 hr, 12 hr)
Reported as:
Mean · Hour (hr)
Part A - Pharmacokinetic of KAE609: Terminal Elimination Half-life (T1/2)
Hour (hr)Part A (Single-ascending Dose (SAD): Cohort A1 (KAE609 10.5 mg)Part A (Single-ascending Dose (SAD): Cohort A2 (KAE609 30 mg)Part A (Single-ascending Dose (SAD): Cohort A3 (KAE609 75 mg)Part A (Single-ascending Dose (SAD): Cohort A4 (KAE609 120 mg)Part A (Single-ascending Dose (SAD): Cohort A5 (KAE609 210 mg)
Part A - Pharmacokinetic of KAE609: Terminal Elimination Half-life (T1/2)27.7 ± 8.8930.5 ± 6.7921.9 ± 6.7638.9 ± 12.829.4 ± 5.39
SecondaryPart A - Pharmacokinetic of KAE609: Clearance From Plasma (CL) Following Drug Administration

Venous whole blood samples were collected for activity-based pharmacokinetics characterization. CL was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics.

Time frame:
Day 1 (-1 hr, 2 min, 10 min, 30 min, 1 hr, 3 hr, 6 hr, 12 hr)
Reported as:
Mean · Milliliter/hour (mL/h)
Part A - Pharmacokinetic of KAE609: Clearance From Plasma (CL) Following Drug Administration
Milliliter/hour (mL/h)Part A (Single-ascending Dose (SAD): Cohort A1 (KAE609 10.5 mg)Part A (Single-ascending Dose (SAD): Cohort A2 (KAE609 30 mg)Part A (Single-ascending Dose (SAD): Cohort A3 (KAE609 75 mg)Part A (Single-ascending Dose (SAD): Cohort A4 (KAE609 120 mg)Part A (Single-ascending Dose (SAD): Cohort A5 (KAE609 210 mg)
Part A - Pharmacokinetic of KAE609: Clearance From Plasma (CL) Following Drug Administration4330 ± 18903150 ± 5072940 ± 1922430 ± 11203500 ± 700
SecondaryPart A - Pharmacokinetic of KAE609: Apparent Volume of Distribution During Terminal Phase (Vz)

Venous whole blood samples were collected for activity-based pharmacokinetics characterization. Vz was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics.

Time frame:
Day 1 (-1 hr, 2 min, 10 min, 30 min, 1 hr, 3 hr, 6 hr, 12 hr)
Reported as:
Mean · Milliliter (mL)
Part A - Pharmacokinetic of KAE609: Apparent Volume of Distribution During Terminal Phase (Vz)
Milliliter (mL)Part A (Single-ascending Dose (SAD): Cohort A1 (KAE609 10.5 mg)Part A (Single-ascending Dose (SAD): Cohort A2 (KAE609 30 mg)Part A (Single-ascending Dose (SAD): Cohort A3 (KAE609 75 mg)Part A (Single-ascending Dose (SAD): Cohort A4 (KAE609 120 mg)Part A (Single-ascending Dose (SAD): Cohort A5 (KAE609 210 mg)
Part A - Pharmacokinetic of KAE609: Apparent Volume of Distribution During Terminal Phase (Vz)154000 ± 20400138000 ± 3400092900 ± 29600124000 ± 32700151000 ± 50400
SecondaryPart B - Pharmacokinetic of KAE609: Maximum Observed Plasma Concentration (Cmax)

Venous whole blood samples were collected for activity-based pharmacokinetics characterization. Cmax was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics.

Time frame:
Days 1 and 5 (-1 hr, 2 min, 10 min, 30 min, 1 hr, 3 hr, 6 hr, 12 hr)
Reported as:
Mean · ng/mL
Part B - Pharmacokinetic of KAE609: Maximum Observed Plasma Concentration (Cmax)
ng/mLPart B (Multiple-ascending Dose (MAD): Cohort B1 (KAE609 60 mg)Part B (Multiple-ascending Dose (MAD): Cohort B2 (KAE609 120 mg)
Day 13920 ± 9994530 ± 705
Day 54630 ± 26705540 ± 2090
SecondaryPart B - Pharmacokinetic of KAE609: Time to Reach the Maximum Concentration After Drug Administration (Tmax)

Venous whole blood samples were collected for activity-based pharmacokinetics characterization. Tmax was calculated from plasma concentration-time data using non-compartmental methods based on the actual time of sample collection and summarized using descriptive statistics.

Time frame:
Days 1 and 5 (-1 hr, 2 min, 10 min, 30 min, 1 hr, 3 hr, 6 hr, 12 hr)
Reported as:
Median · Hour (hr)
Part B - Pharmacokinetic of KAE609: Time to Reach the Maximum Concentration After Drug Administration (Tmax)
Hour (hr)Part B (Multiple-ascending Dose (MAD): Cohort B1 (KAE609 60 mg)Part B (Multiple-ascending Dose (MAD): Cohort B2 (KAE609 120 mg)
Day 10.100 (0.0333 to 0.500)0.167 (0.167 to 0.183)
Day 50.0333 (0.0333 to 0.167)0.167 (0.167 to 0.167)
SecondaryPart B - Pharmacokinetic of KAE609: Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUClast)

Venous whole blood samples were collected for activity-based pharmacokinetics characterization. AUClast was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics.

Time frame:
Day 5 (-1 hr, 2 min, 10 min, 30 min, 1 hr, 3 hr, 6 hr, 12 hr)
Reported as:
Mean · h*ng/mL
Part B - Pharmacokinetic of KAE609: Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUClast)
h*ng/mLPart B (Multiple-ascending Dose (MAD): Cohort B1 (KAE609 60 mg)Part B (Multiple-ascending Dose (MAD): Cohort B2 (KAE609 120 mg)
Part B - Pharmacokinetic of KAE609: Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUClast)58500 ± 23000121000 ± 56100
SecondaryPart B - Pharmacokinetic of KAE609: Area Under the Plasma Concentration-time Curve From Time Zero to 24 Hours (AUC0-24hrs)

Venous whole blood samples were collected for activity-based pharmacokinetics characterization. AUC0-24hrs was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics.

Time frame:
Days 1 and 5 (-1 hr, 2 min, 10 min, 30 min, 1 hr, 3 hr, 6 hr, 12 hr)
Reported as:
Mean · h*ng/mL
Part B - Pharmacokinetic of KAE609: Area Under the Plasma Concentration-time Curve From Time Zero to 24 Hours (AUC0-24hrs)
h*ng/mLPart B (Multiple-ascending Dose (MAD): Cohort B1 (KAE609 60 mg)Part B (Multiple-ascending Dose (MAD): Cohort B2 (KAE609 120 mg)
Day 113200 ± 177016500 ± 2290
Day 520000 ± 489040600 ± 11400
SecondaryPart B - Pharmacokinetic of KAE609: Terminal Elimination Half-life (T1/2)

Venous whole blood samples were collected for activity-based pharmacokinetics characterization. T1/2 was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics.

Time frame:
Days 1 and 5 (-1 hr, 2 min, 10 min, 30 min, 1 hr, 3 hr, 6 hr, 12 hr)
Reported as:
Mean · Hour (hr)
Part B - Pharmacokinetic of KAE609: Terminal Elimination Half-life (T1/2)
Hour (hr)Part B (Multiple-ascending Dose (MAD): Cohort B1 (KAE609 60 mg)Part B (Multiple-ascending Dose (MAD): Cohort B2 (KAE609 120 mg)
Day 125.0 ± 8.1618.1 ± 2.83
Day 535.5 ± 8.5831.9 ± 12.5
SecondaryPart B - Pharmacokinetic of KAE609: Clearance From Plasma (CL) Following Drug Administration

Venous whole blood samples were collected for activity-based pharmacokinetics characterization. CL was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics.

Time frame:
Day 5 (-1 hr, 2 min, 10 min, 30 min, 1 hr, 3 hr, 6 hr, 12 hr)
Reported as:
Mean · Milliliter/hour (mL/h)
Part B - Pharmacokinetic of KAE609: Clearance From Plasma (CL) Following Drug Administration
Milliliter/hour (mL/h)Part B (Multiple-ascending Dose (MAD): Cohort B1 (KAE609 60 mg)Part B (Multiple-ascending Dose (MAD): Cohort B2 (KAE609 120 mg)
Part B - Pharmacokinetic of KAE609: Clearance From Plasma (CL) Following Drug Administration3140 ± 7173160 ± 907
SecondaryPart B - Pharmacokinetic of KAE609: Apparent Volume of Distribution During Terminal Phase (Vz)

Venous whole blood samples were collected for activity-based pharmacokinetics characterization. Vz was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics.

Time frame:
Day 5 (-1 hr, 2 min, 10 min, 30 min, 1 hr, 3 hr, 6 hr, 12 hr)
Reported as:
Mean · Milliliter (mL)
Part B - Pharmacokinetic of KAE609: Apparent Volume of Distribution During Terminal Phase (Vz)
Milliliter (mL)Part B (Multiple-ascending Dose (MAD): Cohort B1 (KAE609 60 mg)Part B (Multiple-ascending Dose (MAD): Cohort B2 (KAE609 120 mg)
Part B - Pharmacokinetic of KAE609: Apparent Volume of Distribution During Terminal Phase (Vz)175000 ± 14700173000 ± 29700

Adverse events

Collected over On-treatment Adverse events (AEs) and serious AEs (including the All-Cause Mortality data table) are presented from first dose of study treatment until last dose of study treatment plus 30 days post treatment, assessed for up to 4 months.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A (Single-ascending Dose (SAD): Cohort A1 (KAE609 10.5 mg)0/6 (0%)0/6 (0%)0/6 (0%)
Part A (Single-ascending Dose (SAD): Cohort A2 (KAE609 30 mg)0/6 (0%)0/6 (0%)1/6 (16.7%)
Part A (Single-ascending Dose (SAD): Cohort A3 (KAE609 75 mg)0/6 (0%)0/6 (0%)1/6 (16.7%)
Part A (Single-ascending Dose (SAD): Cohort A4 (KAE609 120 mg)0/6 (0%)1/6 (16.7%)2/6 (33.3%)
Part A (Single-ascending Dose (SAD): Cohort A5 (KAE609 210 mg)0/6 (0%)0/6 (0%)6/6 (100%)
Part A (Single-ascending Dose (SAD): Pooled KAE6090/30 (0%)1/30 (3.3%)10/30 (33.3%)
Part A (Single-ascending Dose (SAD): Pooled Placebo0/9 (0%)0/9 (0%)5/9 (55.6%)
Part B (Multiple-ascending Dose (MAD): Cohort B1 (KAE609 60 mg)0/6 (0%)0/6 (0%)4/6 (66.7%)
Part B (Multiple-ascending Dose (MAD): Cohort B2 (KAE609 120 mg)0/6 (0%)0/6 (0%)6/6 (100%)
Part B (Multiple-ascending Dose (MAD): Pooled KAE6090/12 (0%)0/12 (0%)10/12 (83.3%)
Part B (Multiple-ascending Dose (MAD): Pooled Placebo0/6 (0%)0/6 (0%)4/6 (66.7%)
Most frequent serious events
Most frequent serious events
EventPart A (Single-ascending Dose (SAD): Cohort A1 (KAE609 10.5 mg)Part A (Single-ascending Dose (SAD): Cohort A2 (KAE609 30 mg)Part A (Single-ascending Dose (SAD): Cohort A3 (KAE609 75 mg)Part A (Single-ascending Dose (SAD): Cohort A4 (KAE609 120 mg)Part A (Single-ascending Dose (SAD): Cohort A5 (KAE609 210 mg)Part A (Single-ascending Dose (SAD): Pooled KAE609Part A (Single-ascending Dose (SAD): Pooled PlaceboPart B (Multiple-ascending Dose (MAD): Cohort B1 (KAE609 60 mg)Part B (Multiple-ascending Dose (MAD): Cohort B2 (KAE609 120 mg)Part B (Multiple-ascending Dose (MAD): Pooled KAE609Part B (Multiple-ascending Dose (MAD): Pooled Placebo
Testicular embryonal carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/60/60/61/60/61/300/90/60/60/120/6
Testicular malignant teratomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/60/60/61/60/61/300/90/60/60/120/6
Most frequent other events
Showing 10 of 29
Most frequent other events
EventPart A (Single-ascending Dose (SAD): Cohort A1 (KAE609 10.5 mg)Part A (Single-ascending Dose (SAD): Cohort A2 (KAE609 30 mg)Part A (Single-ascending Dose (SAD): Cohort A3 (KAE609 75 mg)Part A (Single-ascending Dose (SAD): Cohort A4 (KAE609 120 mg)Part A (Single-ascending Dose (SAD): Cohort A5 (KAE609 210 mg)Part A (Single-ascending Dose (SAD): Pooled KAE609Part A (Single-ascending Dose (SAD): Pooled PlaceboPart B (Multiple-ascending Dose (MAD): Cohort B1 (KAE609 60 mg)Part B (Multiple-ascending Dose (MAD): Cohort B2 (KAE609 120 mg)Part B (Multiple-ascending Dose (MAD): Pooled KAE609Part B (Multiple-ascending Dose (MAD): Pooled Placebo
DizzinessNervous system disorders0/60/60/60/62/62/300/93/64/67/121/6
HeadacheNervous system disorders0/61/60/61/62/64/303/92/63/65/121/6
Semen discolourationReproductive system and breast disorders0/60/61/60/63/64/300/90/60/60/120/6
DiarrhoeaGastrointestinal disorders0/60/60/60/60/60/300/90/62/62/122/6
FatigueGeneral disorders0/60/60/60/60/60/300/90/62/62/121/6
Abnormal sensation in eyeEye disorders0/60/60/60/61/61/300/90/60/60/120/6
Abdominal discomfortGastrointestinal disorders0/60/60/60/61/61/300/90/61/61/121/6
DyspepsiaGastrointestinal disorders0/60/60/60/61/61/300/90/61/61/120/6
EructationGastrointestinal disorders0/60/60/60/60/60/300/91/60/61/120/6
NauseaGastrointestinal disorders0/60/60/61/61/62/300/90/61/61/120/6

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Part A (Single-ascending Dose (SAD): Cohort A1 (KAE609 10.5 mg)Part A (Single-ascending Dose (SAD): Cohort A2 (KAE609 30 mg)Part A (Single-ascending Dose (SAD): Cohort A3 (KAE609 75 mg)Part A (Single-ascending Dose (SAD): Cohort A4 (KAE609 120 mg)Part A (Single-ascending Dose (SAD): Cohort A5 (KAE609 210 mg)Part A (Single-ascending Dose (SAD): Pooled PlaceboPart B (Multiple-ascending Dose (MAD): Cohort B1 (KAE609 60 mg)Part B (Multiple-ascending Dose (MAD): Cohort B2 (KAE609 120 mg)Part B (Multiple-ascending Dose (MAD): Pooled PlaceboTotal
<=18 years0000000000
Between 18 and 65 years66666966657
>=65 years0000000000
Sex: Female, Male
Sex: Female, Male(Participants)Part A (Single-ascending Dose (SAD): Cohort A1 (KAE609 10.5 mg)Part A (Single-ascending Dose (SAD): Cohort A2 (KAE609 30 mg)Part A (Single-ascending Dose (SAD): Cohort A3 (KAE609 75 mg)Part A (Single-ascending Dose (SAD): Cohort A4 (KAE609 120 mg)Part A (Single-ascending Dose (SAD): Cohort A5 (KAE609 210 mg)Part A (Single-ascending Dose (SAD): Pooled PlaceboPart B (Multiple-ascending Dose (MAD): Cohort B1 (KAE609 60 mg)Part B (Multiple-ascending Dose (MAD): Cohort B2 (KAE609 120 mg)Part B (Multiple-ascending Dose (MAD): Pooled PlaceboTotal
Female12111212516
Male54555754141
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part A (Single-ascending Dose (SAD): Cohort A1 (KAE609 10.5 mg)Part A (Single-ascending Dose (SAD): Cohort A2 (KAE609 30 mg)Part A (Single-ascending Dose (SAD): Cohort A3 (KAE609 75 mg)Part A (Single-ascending Dose (SAD): Cohort A4 (KAE609 120 mg)Part A (Single-ascending Dose (SAD): Cohort A5 (KAE609 210 mg)Part A (Single-ascending Dose (SAD): Pooled PlaceboPart B (Multiple-ascending Dose (MAD): Cohort B1 (KAE609 60 mg)Part B (Multiple-ascending Dose (MAD): Cohort B2 (KAE609 120 mg)Part B (Multiple-ascending Dose (MAD): Pooled PlaceboTotal
Hispanic or Latino0000000000
Not Hispanic or Latino66666966657
Unknown or Not Reported0000000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part A (Single-ascending Dose (SAD): Cohort A1 (KAE609 10.5 mg)Part A (Single-ascending Dose (SAD): Cohort A2 (KAE609 30 mg)Part A (Single-ascending Dose (SAD): Cohort A3 (KAE609 75 mg)Part A (Single-ascending Dose (SAD): Cohort A4 (KAE609 120 mg)Part A (Single-ascending Dose (SAD): Cohort A5 (KAE609 210 mg)Part A (Single-ascending Dose (SAD): Pooled PlaceboPart B (Multiple-ascending Dose (MAD): Cohort B1 (KAE609 60 mg)Part B (Multiple-ascending Dose (MAD): Cohort B2 (KAE609 120 mg)Part B (Multiple-ascending Dose (MAD): Pooled PlaceboTotal
American Indian or Alaska Native0000000000
Asian0000000000
Native Hawaiian or Other Pacific Islander0000000000
Black or African American0000000000
White66666966657
More than one race0000000000
Unknown or Not Reported0000000000
08

Study locations

1 site
  • Novartis Investigative Site
    Antwerpen, B-2060, Belgium
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in Nov 2020, 3 months.

Results were first posted in Dec 2021, 1 year 1 month after primary completion.

Of 29 industry-sponsored phase 1 interventional studies under Malaria, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 18. This study's 3 months is below that.

Counting every sponsor, half of 93 studies reached it within 13 months; a quarter within 7 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2020
First posted
Mar 25, 2020
StartActual
Jul 22, 2020
Primary completionActual
Nov 10, 2020
CompletionActual
Nov 10, 2020
Results first posted
Dec 13, 2021
Last update
Dec 13, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 13, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04321252
Collaborators
Wellcome Trust
Responsible party
Sponsor
First posted
Mar 25, 2020
Start date
Jul 22, 2020
Primary completion
Nov 10, 2020
Completion
Nov 10, 2020
Results posted
Dec 13, 2021
Last update
Dec 13, 2021

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: NITD 609

Start the discussion